Neurocrine Biosciences 미래 성장

Future 기준 확인 5/6

Neurocrine Biosciences (는) 각각 연간 30.4% 및 14.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 29.3% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 22% 로 예상됩니다.

주요 정보

30.4%

수익 성장률

29.3%

EPS 성장률

Biotechs 수익 성장	34.7%
매출 성장률	14.6%
향후 자기자본 수익률	22.0%
애널리스트 커버리지	Good
마지막 업데이트	20 Dec 2024

최근 미래 성장 업데이트

Recent updates

수익 및 매출 성장 예측

LSE:0K6R - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	3,265	906	893	1,022	17
12/31/2025	2,756	632	658	765	22
12/31/2024	2,359	426	574	569	21
9/30/2024	2,243	386	440	476	N/A
6/30/2024	2,120	339	495	530	N/A
3/31/2024	1,982	370	614	645	N/A
12/31/2023	1,887	250	362	390	N/A
9/30/2023	1,784	191	385	409	N/A
6/30/2023	1,673	176	281	296	N/A
3/31/2023	1,599	64	237	255	N/A
12/31/2022	1,489	155	323	339	N/A
9/30/2022	1,389	58	177	201	N/A
6/30/2022	1,297	12	133	164	N/A
3/31/2022	1,208	71	102	129	N/A
12/31/2021	1,134	90	233	257	N/A
9/30/2021	1,069	445	328	347	N/A
6/30/2021	1,032	365	251	265	N/A
3/31/2021	1,045	402	266	280	N/A
12/31/2020	1,046	407	218	229	N/A
9/30/2020	1,042	93	222	232	N/A
6/30/2020	1,006	205	337	350	N/A
3/31/2020	887	177	283	295	N/A
12/31/2019	788	37	132	147	N/A
9/30/2019	675	21	82	100	N/A
6/30/2019	605	18	44	71	N/A
3/31/2019	519	-39	0	27	N/A
12/31/2018	451	21	77	101	N/A
9/30/2018	414	10	70	91	N/A
6/30/2018	323	-52	N/A	13	N/A
3/31/2018	233	-106	N/A	-55	N/A
12/31/2017	162	-143	N/A	-94	N/A
9/30/2017	67	-194	N/A	-167	N/A
6/30/2017	6	-220	N/A	-188	N/A
3/31/2017	N/A	-200	N/A	-154	N/A
12/31/2016	15	-141	N/A	-106	N/A
9/30/2016	15	-126	N/A	-90	N/A
6/30/2016	15	-123	N/A	-77	N/A
3/31/2016	15	-107	N/A	-49	N/A
12/31/2015	20	-89	N/A	-38	N/A
9/30/2015	20	-79	N/A	-38	N/A
6/30/2015	20	-60	N/A	-32	N/A
3/31/2015	20	-50	N/A	-56	N/A
12/31/2014	N/A	-61	N/A	-47	N/A
9/30/2014	1	-52	N/A	-43	N/A
6/30/2014	1	-47	N/A	-41	N/A
3/31/2014	2	-46	N/A	-41	N/A
12/31/2013	3	-46	N/A	-30	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 0K6R 의 연간 예상 수익 증가율( 30.4% )이 saving rate( 2.1% 보다 높습니다. ).

수익 vs 시장: 0K6R 의 연간 수익( 30.4% ) UK 시장( 14.8% 보다 빠르게 성장할 것으로 예상됩니다. 14.8% 연간).

고성장 수익: 0K6R 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: 0K6R 의 수익(연간 14.6% ) UK 시장( 3.6% 보다 빠르게 성장할 것으로 예상됩니다. 3.6% 연간).

고성장 수익: 0K6R 의 수익(연간 14.6% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 0K6R 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 22 %)

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/21 11:25
장 마감 주가	2024/12/20 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Neurocrine Biosciences, Inc. 50 애널리스트 중 22 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Martha Freitag	Argus Research Company
Brian Skorney	Baird
Ishan Majumdar	Baptista Research

Neurocrine Biosciences 미래 성장

Future 기준 확인 5/6

주요 정보

최근 미래 성장 업데이트

Neurocrine Biosciences, Inc. Raises Sales Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. Provides Earnings Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. Provides Sales Guidance for the Year 2023

Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023

Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023

Recent updates

Neurocrine Biosciences, Inc. Announces Commercial Availability of CRENESSITY (Crinecerfont) for Children and Adults with Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences, Inc. Announces FDA Approval of Crenessity (Crinecerfont), A First-In-Class Treatment for Children and Adults with Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences, Inc. Presents New KINECT-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health with INGREZZA (Valbenazine) Capsules

Neurocrine Biosciences, Inc. Presents Breadth of Data Demonstrating Holistic Improvements over Time in Patients with Tardive Dyskinesia Following Treatment with INGREZZA (Valbenazine) Capsules

Third quarter 2024 earnings released: EPS: US$1.28 (vs US$0.85 in 3Q 2023)

Neurocrine Biosciences, Inc. (NasdaqGS:NBIX) announces an Equity Buyback for $300 million worth of its shares.

Neurocrine Biosciences, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Neurocrine Biosciences Provides Update on ERUDITE Phase 2 Data for Luvadaxistat in Adults with Cognitive Impairment Associated with Schizophrenia

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 19%

Independent Chairman of the Board recently sold US$2.1m worth of stock

Second quarter 2024 earnings released: EPS: US$0.65 (vs US$0.98 in 2Q 2023)

Neurocrine Biosciences, Inc. Raises Sales Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. Launches INGreZZA® SPRINKLE (valbenazine) Capsules to Ease Administration for Patients Experiencing Dysphagia or Difficulty Swallowing

Neurocrine Biosciences, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH

Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine

Neurocrine Biosciences Announces CEO Changes

Neurocrine Biosciences Announces CEO Changes

Neurocrine Biosciences, Inc. Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis

Neurocrine Biosciences, Inc. and Diurnal Ltd. Presents Baseline Data from the CAHtalyst Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ECE 2024

Neurocrine Biosciences Presents CAHtalyst Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024

Neurocrine Biosciences, Inc. Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults

Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024

Neurocrine Biosciences, Inc. Reaffirms Sales Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules

First quarter 2024 earnings released: EPS: US$0.43 (vs US$0.79 loss in 1Q 2023)

Insufficient new directors

Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community

Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

Neurocrine Biosciences, Inc., Annual General Meeting, May 22, 2024

Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

New minor risk - Shareholder dilution

Full year 2023 earnings released: EPS: US$2.56 (vs US$1.61 in FY 2022)

Neurocrine Biosciences, Inc. Provides Earnings Guidance for the Full Year of 2024

Neurocrine Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 07, 2024

Sosei Heptares’ Partner Neurocrine Biosciences Confirms Its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies

Neurocrine Biosciences, Inc. Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation

Neurocrine Biosciences, Inc. Reports Update on the Phase 2 Clinical Trial

Neurocrine Biosciences® Presents Ingrezza® (Valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated with Huntington's Disease Through Week 50 At Huntington Study Group 2023

New minor risk - Shareholder dilution

Neurocrine Biosciences, Inc. Provides Sales Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$0.85 (vs US$0.71 in 3Q 2022)

Neurocrine Biosciences, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Application for Ingrezza®? (Valbenazine) Oral Granules Sprinkle Formulation

Neurocrine Biosciences, Inc. Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)

Neurocrine Biosciences Inc. Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults

Neurocrine Biosciences, Inc. Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders Demonstrating Comparable Improvement over Time in Tardive Dyskinesia Severity and Impact Following Treatment with INGREZZA (Valbenazine) Capsules

Neurocrine Biosciences, Inc. Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease

Neurocrine Biosciences, Inc. Announces FDA Approval of INGreZZA (valbenazine) Capsules for the Treatment of Chorea Associated with Huntington's Disease

Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.98 (vs US$0.18 loss in 2Q 2022)

Neurocrine Biosciences, Inc. Announces Retirement of Eiry W. Roberts as Chief Medical Officer

Neurocrine Biosciences, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Neurocrine Biosciences, Inc. Presents INGreZZA(R) (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate

Neurocrine Biosciences, Inc. Announces Publication of Full KINECT(TM)-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in the Lancet Neurology

Neurocrine Biosciences, Inc. Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023

Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023

First quarter 2023 earnings released: US$0.79 loss per share (vs US$0.15 profit in 1Q 2022)

Insufficient new directors

Full year 2022 earnings released: EPS: US$1.61 (vs US$0.95 in FY 2021)

Neurocrine Biosciences, Inc. to Report Q4, 2022 Results on Feb 06, 2023

Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as A Treatment for Chorea Associated with Huntington Disease

Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-And-Wave During Sleep

Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022

Third quarter 2022 earnings released: EPS: US$0.71 (vs US$0.24 in 3Q 2021)

Neurocrine Biosciences, Inc. Provides Sales Guidance for the Full-Year 2022